Trials / Recruiting
RecruitingNCT05663775
Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)
Prophylactic Oral Mesalamine for the Prevention of Immune-Related Colitis in Patients Treated With Ipilimumab/Nivolumab
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- AHS Cancer Control Alberta · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study team's principal interest is to address the question, "Will prophylactic treatment with mesalamine reduce the incidence and severity of immune-related diarrhea occurring secondarily to treatment with ipi/nivo?"
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mesalamine | Mesalamine, also known as 5-aminosalicylic acid (5-ASA) |
Timeline
- Start date
- 2024-08-20
- Primary completion
- 2026-08-01
- Completion
- 2027-08-01
- First posted
- 2022-12-23
- Last updated
- 2025-06-27
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT05663775. Inclusion in this directory is not an endorsement.